T cells, or CD56
1 NK cells expressing NKG2D. We collected blood samples 4 times, and the FACS analysis was also performed by dividing into 4 times. Therefore, final data were represented as a fold change of each cells expressing NKG2D over the healthy control (control set to 1). The patients were segregated into 2 or 3 subgroups according to AA severity, activity, type, and treatment modalities for subgroup analysis. Statistical analysis was performed using the ManneWhitney U test and KruskaleWallis analysis. Double-labeling immunofluorescence microscopy in 2 representative cases using freshly frozen specimens was also performed.
The results showed that the levels of NKG2D 1 CD8 1 T cells and NKG2D 1 CD56 1 NK cells were higher in the AA group compared with the control group (P \ .05). Interestingly, a 2.49-fold increase in the CD4
1 T cells subset expressing NKG2D was detected in the peripheral blood from patients with AA compared with healthy controls (P \ .05; Fig 1) . Although not statistically significant, the proportion of NKG2D 1 CD4 1 T cells was lower in patients who had mild severity AA and in those who received systemic immunosuppressive therapy. Double label immunofluorescence revealed NKG2D 1 cells coexpressed CD4 around the hair follicles of the AA lesion (Fig 2) .
Recently, the role of NKG2D 1 CD4 1 T cells in other chronic autoimmune diseases, such as Crohn's disease and rheumatoid arthritis, was highlighted. 4 A subset of CD4 1 T cells expressing NKG2D was higher in the lamina propria of patients with Crohn's disease. 5 These NKG2D 1 CD4 1 T cell clones were functionally active through major histocompatibility complex class I-related chain A (MICA) eNKG2D interactions, producing IFN-and killing targets expressing MICA. 5 We hypothesize that NKG2D Classic and HIV-related Kaposi sarcoma treated with 0.1% topical timolol gel
To the Editor: During the last 12 months, we treated 4 cases of cutaneous Kaposi sarcoma (KS) with 0.1% topical timolol gel (Table I) . Of the 4 cases, 3 were classic KS, whereas 1 was HIV-associated KS. In the first 3 cases, 0.1% timolol gel was applied twice a day until resolution. Blood pressure, glucose, and heart pulses were assessed every week. The patients showed complete resolution of lesions, and of edema and pain, with no reported adverse events 4 to 5 weeks later. Of note, 1 patient was under treatment with 10 mg/d of oral bisoprolol. It is not known if the ongoing bisoprolol treatment played any synergistic therapeutic role along with topical timolol. These 3 cases confirmed the 2 observations reported in literature regarding the efficacy of topical timolol on classic KS 1, 2 ; however, in our patients, we obtained a faster response with a reduced and safer timolol concentration (0.1% instead of 0.5%), indicating that a higher dosage might be unnecessary and perhaps even less efficacious.
The fourth case was a 45-year-old man who presented with a rapidly growing lesion on the inner upper aspect of his right arm; this lesion had first appeared 4 weeks earlier (Fig 1, A, and Table I ). After histologic confirmation of KS, we started treatment with 0.1% topical timolol twice a day based on our experience with the previous 3 cases. The treatment continued with significant improvement by the end of the sixth week (Fig 1, B) .
Around the fifth week of therapy, the patient reported asthenia and unexplained fever and did not respond to systemic antibiotics. Chest x-ray and sputum examination for acid-fast bacilli were positive for active tuberculosis infection. Tests for hepatitis B virus, hepatitis C virus, and syphilis were negative, whereas serology for HIV was positive. The CD4 count was 360 cells/mm 3 . Topical timolol was withdrawn as a precaution, and by the end of the eighth week, antituberculosis therapy recommended by the World Health Organization was started as was highly active antiretroviral therapy with emtricitabine/tenofovir disoproxil fumarate combination once daily along with efavirenz once daily. At the 4-month follow-up, the patient did not show any sign of recurrence or spreading of KS. To our knowledge, these are the first reports of patients responding to a topical beta-blocker. KS usually develops in the later stages of HIV/AIDS; only rarely today is KS a presenting feature of HIV infection. Highly active antiretroviral therapy might have played a role in maintaining the remission of the KS lesion treated with timolol, particularly in avoiding the onset of newly spread lesions; indeed, it is known that in patients on highly active antiretroviral therapy, KS lesions may regress depending on the degree of restoration of the immune system. 4 Nonetheless, the therapeutic effect of the topical beta-blocker in our case was evident, as no other drugs were administered in the first 6 weeks.
Our case series confirms and adds to the mounting evidence of the efficacy of topical betablockers on different forms of KS. To the Editor: Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicle that is characterized by painful, deep-seated inflamed nodules and fistulous tracts in most commonly, axillae, inguinal, and anogenital regions.
1 HS usually presents after puberty and predominately occurs in women with a female-to-male ratio of 3:1. The influence of hormones has been suspected in women with HS for more than 60 years yet has not been proven. 2 To date, few studies have described the influence of menses and pregnancy on HS symptoms, with deterioration during menses and amelioration during pregnancy being most frequently reported. 3, 4 However, these studies are limited by a relatively small sample size and many are dated, with more than half of the studies being published between 1986 and 1996. Moreover, the 2 most recent studies did not report on both menses and pregnancy.
We conducted a survey-based cross-sectional study to assess the influence of menses and pregnancy on HS symptoms in the Department of Dermatology at Erasmus University Medical Center (Rotterdam, The Netherlands). One hundred eightysix subjects answered the question on the influence of menses, 96 on pregnancy, and 75 on both (Table I) . Of the 186 respondents, 43% reported a deterioration of HS around menses, but 53.8% reported no change in symptoms. In 30.2% of subjects, pregnancy resulted in an amelioration of symptoms, while 53.1% reported no effect on symptoms. An amelioration during pregnancy was more frequently reported by subjects who experienced a deterioration during menses than by subjects who with no effect or an amelioration of HS symptoms perimenstrually (P ¼ .01). No correlation was found between Hurley stage and the course of perimenstrual symptoms (P ¼ .39) or symptoms during pregnancy (P ¼ .97). Furthermore, there was no correlation between body mass index and the severity of HS symptoms during menses or pregnancy (respectively, P ¼ .49, P ¼ .26).
The results of the previous smaller studies investigating the prevalence of perimenstrual flares and change of symptoms during pregnancy are in line with our findings. A flare of HS symptoms around menses was most frequently reported, by 44% to 63% of women. 3, 4 An amelioration of symptoms during pregnancy was most often described, namely in 20% to 83% of subjects. 3, 4 
